{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T15:02:12.834178",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 87,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "mortality",
        "survival",
        "median survival (by HCC stage)",
        "5-year survival",
        "long-term survival",
        "improved survival",
        "death (partitioned survival model)",
        "perioperative mortality"
      ],
      "response_measures": [
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "objective response rate (ORR)",
        "tumor response rate",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "response assessment (multiphase computed tomography with contrast)",
        "response assessment (magnetic resonance imaging with contrast)",
        "complete response (CR)",
        "partial response (PR)",
        "partial response",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "success rate (downstaging/bridging)",
        "local tumour control",
        "objective tumour response"
      ],
      "progression_measures": [
        "progression-free survival (PFS)",
        "progression-free survival (stratified log-rank)",
        "progression-free survival (partitioned survival model)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression",
        "time-to-progression",
        "time to progression of the tumor",
        "progressive illness (partitioned survival model)",
        "disease progression",
        "tumour spread (TNM system)",
        "recurrence detection",
        "disease recurrence",
        "risk of recurrence",
        "recurrence"
      ],
      "other_efficacy": [
        "tumor reduction",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "time to symptomatic progression (TTSP)",
        "time to symptom progression",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-HCC18)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to clinically meaningful worsening of EQ-5D",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to deterioration",
        "prognosis based on diameter of largest tumour",
        "prognosis based on number of tumours in the liver",
        "presence of extrahepatic tumour",
        "microinvasion",
        "tumour stage at diagnosis",
        "completeness of ablation (multiphase computed tomography with contrast)",
        "follow-up examination after ablation (magnetic resonance imaging)",
        "follow-up examination after ablation (multiphase computed tomography)"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (grade 3 or higher)",
        "adverse events (CTCAE v5.0)",
        "adverse events (serious)",
        "adverse events (leading to discontinuation)",
        "adverse events (occurring in >X% of patients)",
        "treatment-emergent adverse events (TEAEs)",
        "adverse reactions (general)",
        "serious adverse reactions (grade 3/4)",
        "adverse reactions of grade 3 or higher",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "treatment-related deaths",
        "fatal adverse events",
        "complication incidence",
        "complications",
        "post-treatment complications",
        "serious complications",
        "intraoperative complications",
        "long-term treatment-related complications",
        "bleeding",
        "haemorrhagic events",
        "tumour haemorrhage",
        "thromboembolic events",
        "ischaemic stroke",
        "respiratory failure",
        "sudden death",
        "liver failure",
        "hepatotoxicity",
        "nutrition (EORTC QLQ-HCC18)",
        "pain (EORTC QLQ-HCC18)",
        "pain (EORTC QLQ-C30)",
        "pain",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "fever",
        "diarrhoea",
        "fatigue (EORTC QLQ-HCC18)",
        "fatigue",
        "nausea",
        "neutropenia",
        "hand-foot skin reaction",
        "hand feeding reactions",
        "skin rash",
        "rash",
        "desquamation",
        "skin desquamation",
        "hypody",
        "hypothyroidism",
        "hypertension",
        "loss of appetite",
        "decreased appetite",
        "weight loss",
        "alopecia",
        "secondary cancer",
        "lymphoedema",
        "pleural effusion",
        "dyspnoea",
        "cough",
        "back pain",
        "limb pain",
        "joint pain",
        "portal vein thrombosis",
        "grade 3 adverse reactions",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "increased ALT activity",
        "ALT increase",
        "AST increase",
        "creatinine increase",
        "hypocalcaemia",
        "morbidity",
        "perioperative morbidity",
        "postoperative softening",
        "gallbladder abscess",
        "leukaemia"
      ],
      "serious_events": [
        "serious adverse events",
        "serious complications",
        "treatment-related deaths",
        "fatal adverse events"
      ],
      "discontinuations": [
        "adverse events (leading to discontinuation)",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-5L",
        "EQ-5D-3L",
        "EQ-5D VAS",
        "EQ VAS (Euro QoL visual analogue scale)",
        "health status (EQ-5D visual analogue scale)",
        "global health status (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "FACT-G (Functional Assessment of Cancer Therapy â€“ General)",
        "FACT-G",
        "FACT-Hep",
        "overall quality of life (measured with a validated and reliable instrument)",
        "quality of life weights",
        "health-related quality of life (HRQoL)",
        "health-related quality of life",
        "quality of life"
      ],
      "functional_status": [
        "performance status",
        "overall condition (ECOG Performance Status)",
        "role functioning (EORTC QLQ-C30)"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "pain (EORTC QLQ-C30)",
        "pain",
        "fatigue (EORTC QLQ-HCC18)",
        "fatigue",
        "nausea",
        "diarrhoea",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "body image (EORTC QLQ-HCC18)",
        "nutrition (EORTC QLQ-HCC18)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (economic outcomes)",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness analysis",
        "cost-benefit analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "health state utility values"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "number needed to harm (NNH)",
        "number needed to treat (NNT)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "pharmacokinetic parameters",
        "plasma pharmacokinetics lenvatinib exposure parameters",
        "vital signs",
        "RECIST criteria",
        "Barcelona Clinic Liver Cancer (BCLC) staging system",
        "severity of underlying liver disease",
        "liver function",
        "liver function (Child-Pugh scale)",
        "microscopic detection of cancer (histological and prognostic parameters)",
        "immunohistochemical confirmation of hepatocytic origin",
        "genetic diagnosis (identification of subtypes)"
      ],
      "biomarkers": [
        "blood and tumour biomarkers correlated with clinical outcomes"
      ]
    }
  }
}